Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
February 23, 2023 16:05 ET
|
Relay Therapeutics, Inc.
Advanced RLY-4008: Reported interim data with 88% overall response rate at pivotal dose and 63% across all doses in pan-FGFR treatment-naïve, FGFR2-fusion cholangiocarcinoma patients & announced...
Relay Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
February 16, 2023 16:05 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics to Participate in Guggenheim Healthcare Talks | Oncology Day
February 02, 2023 07:30 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Guggenheim Healthcare Talks | Oncology Day on...
Relay Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 07:30 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
November 07, 2022 07:30 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two fireside chats this month at the H.C. Wainwright 3rd Annual Precision...
Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
November 03, 2022 16:05 ET
|
Relay Therapeutics, Inc.
Shared 88% overall response rate (ORR) from interim data of RLY-4008 in pan-FGFR treatment (FGFRi)-naïve FGFR2-fusion cholangiocarcinoma (CCA) patients treated at the pivotal dose at European Society...
Relay Therapeutics to Announce Third Quarter 2022 Financial Results and Corporate Highlights
October 27, 2022 16:05 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics to Participate in Fireside Chat at Bank of America Securities 2022 Precision Oncology Conference
September 26, 2022 07:30 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
September 12, 2022 21:30 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics Announces Proposed Public Offering of Common Stock
September 12, 2022 07:00 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...